Sid Yadav MD, FACP
@SidYadavMD
Breast & GYN Oncologist @MayoCancerCare | Associate Professor of Oncology @MayoClinic | Research in DNA damage repair deficiencies & familial cancers.
In oncology, we don’t usually love overlapping Kaplan-Meier curves. Except that sometimes we really do. Thanks to NSABP-B51, countless pts will be spared the toxicity of nodal irradiation, and many will live free from a permanent lymph edema that would have impacted their lives.
In women with node-positive breast cancer whose nodes became free of disease after neoadjuvant therapy, regional nodal irradiation did not reduce breast cancer recurrence or improve survival. Full results from a phase 3 trial: nej.md/4dM6LjD
🚨A must-read review in @NatRevClinOncol ➡️EMT and cancer: what clinicians should know 🎯Cancer cell plasticity fuels metastasis & treatment resistance. @OncoAlert @DrYukselUrun #cancer #Oncology #MedX 👉doi.org/10.1038/s41571…
I felt surrounded by brilliant, innovative, patient centered colleagues today. Thank you all for coming to DC
Incredibly proud and grateful for the success of this @NRGonc ADC Symposium in DC! Packed room, outstanding talks from all faculty, and plenty of food for thought to push forward the field of ADC across oncology fields.
#AudioVisualAbstract : Mainstream Germline #GeneticTesting with Expanded Eligibility for Early #BreastCancer Patients in a Large Integrated Health System rdcu.be/evQws @belenmerck @SyedAAhmad5
We see it daily. NCCN calls for plasma and tissue NGS testing for NSCLC. (+25% better yield) Market data shows as few as 40% who need it get it. Too many patients on the wrong therapy due to this. 50% of these patients never make it to 2nd line therapy.
Despite clear guidelines, germline genetic testing remains underutilized in patients with metastatic breast cancer. In our new study published in JCO Precision Oncology, we evaluated >15,000 patients with metastatic breast cancer and found that fewer than half received germline…
Grateful for the trust my patients place in me, and truly honored to be recognized as one of the highest performing physicians (99th percentile) at @MayoClinic based on patient satisfaction surveys. Among the many hats I wear, caring for patients with cancer is the one I cherish…
Finally done! It’s been a marathon of a week getting 9 abstracts in for San Antonio Breast Cancer Symposium —5 as first or senior author. Time to celebrate! @SABCSSanAntonio
A cheaper way to identify HRD positive tumors that might benefit from PARPi+Bev maintenance in ovarian cancer? In the PAOLA-1/ENGOT-ov25 trial (n=519), BRCA1/RAD51C methylation testing showed PFS & OS benefit with bevacizumab+olaparib maintenance. ✅ Identified ~85% of HRD+…
अमेरिकाको मेयो क्लिनिकका क्यान्सर विशेषज्ञ डा सिद्धार्थ यादवले अमेरिकन सोसाइटी अफ क्लिनिकल अन्कोलोजीको वार्षिक सम्मेलनमा स्तनक्यान्सर भएका महिलाको दीर्घकालीन स्वास्थ्य परिणाममा जेनेटिक म्यूटेसनले पार्नेप्रभाव वारे नयाँअध्ययन सार्वजनिक गरेका छन @SidYadavMD nepalhealthpress.com/noncommunicabl…
Honored to have presented 1 oral abstract and presented/co-authored 4 posters at #ASCO25 —an incredible experience representing the impactful research led by @MayoCancerCare . Grateful to my collaborators for their partnership and support.
Starting in 25 minutes. I will be presenting the OS data based on germline PV carrier status among approximately 25,000 women with breast cancer in the CARRIERS study. Hall S103. #ASCO25
@FASinicropeMD of @MayoCancerCare @MayoClinic presenting results of ATOMIC trial at @ASCO #asco25 #plenary. Proud of our colleague!
Today at #ASCO25, I’ll be presenting findings from the VERITAC-2 study on vepdegestrant in ER+/HER2- metastatic #breastcancer, the most common subtype, demonstrating a 43% risk reduction in progression/death for ESR1-mutant patients. @NEJM nejm.org/doi/abs/10.105…
I am so lucky to be in Berlin during the Victory Day celebrations—marking 80 years since the end of World War II. Being here, surrounded by history, is a powerful reminder of how far we’ve come and why it’s so important to remember the past. So we never repeat its mistakes.
Recently published: #BreastCancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2, by Allison W. Kurian et al. doi.org/10.1158/2767-9… @StanfordMed @SidYadavMD @GENES_PK #BreastCancerRisk #OpenAccess
Excited to share our new publication led by @AllisonKurian and Dr. Fergus Couch, exploring how established breast cancer risk factors affect women with germline pathogenic variants (PVs) in BRCA1/2, ATM, CHEK2, and PALB2. Using data from nearly 13,000 participants in the Women’s…
Mind expanding session on #ImplementationScience at #SCHD25! Dr. Lifang Hou's presentation on cancer prevention in global settings, with panel insights from Salene M. W. Jones, PhD; Katrina Ortblad, ScD, MPH, and session chairs @SidYadavMD & Catherine Duggan, PhD, illustrated the…
A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new options for our pts!